Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance.

Journal of endocrinological investigation - 1 May 2007

Walton-Betancourth S, Martinelli C E, Thalange N K, Dyke M P, Acerini C L, White S, Camacho-Hübner C, Savage M O

Abstract excerpt

We report a child with Noonan syndrome, referred with severe short stature (height--5.4 SD) and biochemical features of GH resistance. The Noonan syndrome phenotype was confirmed by a clinical geneticist, however analysis of the protein tyrosine phosphatase nonreceptor type 11 (PTPN11) gene showe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child, Preschool
Share to Genotype
Share to Growth Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Human Growth Hormone

Share to Intracellular Signaling Peptides and Proteins

Share to Noonan Syndrome

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Protein Tyrosine Phosphatases

Source

Identifiers

PMID: 17598979
DOI: 10.1007/BF03346324

Genes

PTPN11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17598979-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance.PMID 17598979Read ↗

Efficacy and safety of growth hormone therapy in children with Noonan syndrome.Semantic proximity Read ↗

Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 Gene mutationSemantic proximity Read ↗

Abnormal growth in noonan syndrome: the challenge of optimal therapy.Semantic proximity Read ↗

PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.Semantic proximity Read ↗

Noonan syndrome: relationships between genotype, growth, and growth factors.Semantic proximity Read ↗

Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.Semantic proximity Read ↗

GH therapy in Noonan syndrome: Review of final height data.Semantic proximity Read ↗

Growth hormone therapy in Noonan syndrome: growth response and characteristics.Semantic proximity Read ↗

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.Semantic proximity Read ↗

Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.Semantic proximity Read ↗

Expanding the genetic spectrum of Noonan syndrome.Semantic proximity Read ↗

Noonan syndrome, the Ras-MAPK signalling pathway and short stature.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.